FAQ on Nutriband Inc.'s Innovation in Abuse-Deterrent Drug Delivery

What is Nutriband Inc. known for?

Nutriband Inc. is known for developing a portfolio of transdermal pharmaceutical products, particularly its AVERSA abuse-deterrent technology designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

What are Nutriband’s lead products under development?

Nutriband’s lead products under development include an abuse-deterrent fentanyl patch and a buprenorphine candidate, both incorporating its AVERSA technology.

Why is AVERSA technology significant?

AVERSA technology is significant because it can be incorporated into any transdermal patch to deter abuse and misuse of drugs with abuse potential, addressing critical public health needs.

What potential sales are projected for AVERSA Fentanyl and AVERSA Buprenorphine?

AVERSA Fentanyl is projected to reach peak annual U.S. sales of $80 to $200 million, while AVERSA Buprenorphine is projected to achieve peak U.S. sales between $70 and $130 million upon approval.

How does Nutriband’s technology benefit from global patent protection?

Nutriband’s technology is on track for global patent protection, which secures the company’s innovations and supports its scalable platform for abuse-deterrent drug delivery.

Where can I find more information about Nutriband Inc.?

More information about Nutriband Inc. can be found on their website at www.Nutriband.com or in the company’s newsroom at https://ibn.fm/NTRB.

What is BioMedWire’s role in covering Nutriband Inc.?

BioMedWire specializes in communications for the Biotechnology, Biomedical Sciences, and Life Sciences sectors, providing news and updates on companies like Nutriband Inc. to a wide audience.

How can investors stay updated on Nutriband Inc.?

Investors can stay updated on Nutriband Inc. by visiting the company’s newsroom at https://ibn.fm/NTRB for the latest news and updates.